Magnus Doverskog, PhD, MBA

After post-doc studies at EMBL in Heidelberg, Dr. Doverskog became an industry scientist, with management positions in drug discovery at Biovitrum AB, Stockholm. He was recruited to Karolinska Development, as a project manager and CEO in the portfolio company IMED. His present assignment is as a Chief Scientific Officer (CSO) at Umecrine Cognition, located at the Karolinska Institute, where he served as CEO for 10 years. As the CSO his focus is to lead the development of the company’s compounds (e.g. golexanolone) in clinical development for cognitive disorders. Dr Doverskog’s recent contributions concern the understanding of how to effectively treat CNS symptoms and increase quality of life in disorders such as Parkinson’s disease. Golexanolone is a novel GABA-A receptor modulating compound that normalizes glia activation and a-syn expression in a 6-OHDA model and that shows promise for Rx of cognitive and sleep disorders due to neuroinflammation and elevated GABAergic signaling.